Unigene Laboratories
 | This article needs additional citations for verification. (March 2012) |
| Company type | Public |
|---|---|
| OTC Pink No Information: /quote UGNEQ | |
| Industry | Biotechnology |
| Founded | 1980 |
| Defunct | July 2, 2023 |
| Fate | Bankrupt |
| Headquarters | , |
Key people |
|
| Products | Research and development of peptides for medical purposes |
Number of employees | 53 (2020) |
| Website | www |
Unigene Laboratories was an American biopharmaceutical company, engaged in the research and development of peptides for medical purposes. The company was founded in 1980 and is located in New Jersey.[1][2]
The company's primary focus is on the development of calcitonin and related peptides for the treatment of osteoporosis. The company has licensed worldwide rights to its oral parathyroid hormone ("PTH") to GlaxoSmithKline.[3][4]
Unigene filed for Chapter 7 bankruptcy on July 2, 2013 in the United States Bankruptcy Court of the District of New Jersey. The Chapter 7 case is being administered under case No. 13-24696.
See also
[edit]References
[edit]- ^ "Unigene Laboratories Overview". Pitchbook. Retrieved February 21, 2025.
- ^ "Unigene Drops a Third of Its Staff and Restructures to Achieve 2010 Savings of $9–10M". Genetic Engineering & Biotechnology News. December 9, 2009.
- ^ "Unigene Divests Site-Directed Bone Growth Patents to Kieran Murphy". Genetic Engineering & Biotechnology News. September 21, 2011.
- ^ "GlaxoSmithKline to pay $420 Million for drug rights". New York Times. April 16, 2002.